A randomized, double-blinded, placebo-controlled multicenter trial was conducted to assess the cyclosporine-sparing effect of polyunsaturated fatty acids. Dogs with atopic dermatitis (n = 36) already receiving cyclosporine were given either a combined omega-3/omega-6 fatty acid product or placebo orally for 12 weeks. The dogs were examined monthly by a dermatologist and scored based on the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03). Pruritus, quality of life, overall condition, and coat quality were scored by the owner. Improvements in CADESI-03 or pruritus scores of at least 25% resulted in cyclosporine dosage decreases of about 25%. The median pruritus score was significantly improved in the fatty acid group compared with the placebo group with a significantly greater decrease in cyclosporine dosage. There was no significant difference in CADESI-03 changes between groups. The data suggest that omega-3/omega-6 fatty acid supplementation may have a cyclosporine-sparing effect in atopic dogs. Trial sponsored by Novartis.—Müller M, Linek M, Röthig A, Löwenstein C, Mueller RS